Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Elizabeth J Davis

Showing results (41-50 of 50) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 50 results.
JAMA Oncology|September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial UpdateAlice P Chen, Christina L Rosenberger, Nancy Moore, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 16, 2022
Correction to: Machine learning for rhabdomyosarcoma histopathologyArthur O Frankel, Melvin Lathara, Celine Y Shaw, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 22, 2022
Machine learning for rhabdomyosarcoma histopathologyArthur O Frankel, Melvin Lathara, Celine Y Shaw, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
The New England Journal of Medicine|September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part SarcomaAlice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025Margaret von Mehren, John M Kane, Samantha A Armstrong, et al.
Cancers|September 9, 2022
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort StudyMichael J Wagner, Cassandra Hennessy, Alicia Beeghly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2022
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled TrialMrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, et al.
Cancer Treatment Reviews|August 28, 2022
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatmentsSilvia Stacchiotti, Anna Maria Frezza, George D Demetri, et al.
Pageof 5

Showing results (41-50 of 50) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 50 results.
JAMA Oncology|September 23, 2018
Fatal Toxic Effects Associated With Immune Checkpoint Inhibitors: A Systematic Review and Meta-analysisDaniel Y Wang, Joe-Elie Salem, Justine V Cohen, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 18, 2026
Atezolizumab for Alveolar Soft Part Sarcoma: A Clinical Trial UpdateAlice P Chen, Christina L Rosenberger, Nancy Moore, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|May 16, 2022
Correction to: Machine learning for rhabdomyosarcoma histopathologyArthur O Frankel, Melvin Lathara, Celine Y Shaw, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc|April 22, 2022
Machine learning for rhabdomyosarcoma histopathologyArthur O Frankel, Melvin Lathara, Celine Y Shaw, et al.
Cancer|October 29, 2025
Phase 1 clinical trial of the ataxia telangiectasia and Rad3-related inhibitor berzosertib with irinotecan in patients with advanced solid tumors (ETCTN 9938)Liza C Villaruz, Jingxiao Jin, Hong Wang, et al.
The New England Journal of Medicine|September 6, 2023
Atezolizumab for Advanced Alveolar Soft Part SarcomaAlice P Chen, Elad Sharon, Geraldine O'Sullivan-Coyne, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|February 11, 2026
NCCN Guidelines® Insights: Soft Tissue Sarcoma, Version 1.2025Margaret von Mehren, John M Kane, Samantha A Armstrong, et al.
Cancers|September 9, 2022
Demographics, Outcomes, and Risk Factors for Patients with Sarcoma and COVID-19: A CCC19-Registry Based Retrospective Cohort StudyMichael J Wagner, Cassandra Hennessy, Alicia Beeghly, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 8, 2022
Selinexor in Advanced, Metastatic Dedifferentiated Liposarcoma: A Multinational, Randomized, Double-Blind, Placebo-Controlled TrialMrinal M Gounder, Albiruni Abdul Razak, Neeta Somaiah, et al.
Cancer Treatment Reviews|August 28, 2022
Retrospective observational studies in ultra-rare sarcomas: A consensus paper from the Connective Tissue Oncology Society (CTOS) community of experts on the minimum requirements for the evaluation of activity of systemic treatmentsSilvia Stacchiotti, Anna Maria Frezza, George D Demetri, et al.
Pageof 5